Tesamorelin Dosing: What Clinics Prescribe and What to Expect

Tesamorelin Dosing: What Clinics Prescribe and What to Expect (2026)

Key Takeaways

• Tesamorelin's FDA-approved dose is 2 mg subcutaneous daily for HIV-associated lipodystrophy^[1]
• The peptide requires daily injection with 27-gauge needles into abdominal subcutaneous tissue^[1]
• Clinical trials demonstrate efficacy at the single 2 mg dose without titration requirements^[2]
• Reconstitution requires sterile water for injection, creating a 1 mg/mL solution^[1]
• Treatment duration in pivotal trials ranged from 26 to 52 weeks with sustained efficacy^[2]
• Storage requires refrigeration at 36-46°F (2-8°C) before and after reconstitution^[1]

What Is Tesamorelin?

Tesamorelin is a synthetic 44-amino acid analog of human growth hormone-releasing hormone (GHRH) with enhanced stability through N-terminal modification.^[1] The peptide activates GHRH receptors in the anterior pituitary gland, stimulating endogenous growth hormone (GH) secretion with a plasma half-life of approximately 26 minutes.^[1] Unlike direct GH administration, tesamorelin preserves the natural pulsatile pattern of GH release, maintaining physiological feedback mechanisms.

The FDA approved tesamorelin in November 2010 specifically for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.^[1] This represents the only FDA-approved therapeutic indication for the peptide, with clinical trials demonstrating significant reductions in visceral adipose tissue (VAT) of 15-18% compared to placebo.^[2] For comprehensive information about tesamorelin's mechanism and clinical applications, see our complete tesamorelin profile.

Standard Dosing Protocols

The FDA prescribing information establishes a single dosing regimen for tesamorelin: 2 mg administered subcutaneously once daily.^[1] This dose was selected based on Phase II dose-ranging studies that evaluated 1 mg and 2 mg daily doses, with the higher dose demonstrating superior efficacy for visceral fat reduction.^[2] No loading dose or titration schedule is required, as patients begin treatment at the therapeutic dose.

Clinical trials supporting FDA approval used this standardized 2 mg daily protocol across multiple studies.^[2] The pivotal Phase III trials enrolled 816 patients with HIV-associated lipodystrophy, demonstrating consistent efficacy at this dose level.^[2] Bioavailability studies indicate subcutaneous administration achieves peak plasma concentrations within 15 minutes, with complete clearance within 4 hours.^[1]

Titration Schedules

Tesamorelin dosing does not require titration, as clinical trials initiated treatment at the therapeutic 2 mg dose without dose escalation.^[1] This differs from many peptide therapies that require gradual dose increases to minimize side effects. The absence of titration reflects tesamorelin's favorable tolerability profile, with injection site reactions being the primary adverse event in 26% of patients.^[2]

However, some clinicians may consider a brief adaptation period for patients experiencing injection site reactions or mild systemic effects.^[3] In such cases, an unofficial protocol might involve 1 mg daily for the first week, followed by the standard 2 mg dose. This approach lacks formal clinical validation but may improve treatment adherence in sensitive patients.

Administration Protocol

Tesamorelin requires subcutaneous injection using a 27-gauge needle with 0.5-1.0 mL injection volume.^[1] The recommended injection sites include the abdominal wall, avoiding the 2-inch radius around the navel to prevent inadvertent intramuscular injection.^[1] Patients should rotate injection sites within the abdominal region to prevent lipodystrophy or injection site reactions.

The peptide comes as lyophilized powder requiring reconstitution with 2.1 mL sterile water for injection, creating a 1 mg/mL solution.^[1] After reconstitution, the solution remains stable for 3 days when refrigerated at 36-46°F (2-8°C).^[1] Patients should inject the medication at the same time each day, preferably in the evening before bedtime to align with natural GH secretion patterns.

Injection technique involves pinching abdominal skin to create a fold, inserting the needle at a 45-90 degree angle depending on subcutaneous tissue thickness, and injecting slowly over 5-10 seconds.^[1] The injection site should be rotated systematically to prevent tissue damage or reduced absorption. For detailed reconstitution instructions, consult our peptide reconstitution guide.

Dosing by Use Case

HIV-Associated Lipodystrophy

The FDA-approved indication uses 2 mg subcutaneous daily for patients with HIV-associated lipodystrophy and excess abdominal fat.^[1] Clinical trials required baseline visceral adipose tissue (VAT) area ≥100 cm² measured by CT scan at the L4-L5 vertebral level.^[2] Treatment duration in pivotal studies was 26 weeks, with extension studies continuing to 52 weeks demonstrating sustained efficacy.^[2]

Patients typically observe initial changes in abdominal circumference after 12-16 weeks of treatment, with maximal VAT reduction occurring by 26 weeks.^[2] The mean VAT reduction in clinical trials was 15.2% compared to 5.1% with placebo (p<0.001).^[2] Concurrent antiretroviral therapy requirements include stable regimens for at least 8 weeks before tesamorelin initiation.

Research Applications

Off-label research uses explore tesamorelin for non-alcoholic fatty liver disease (NAFLD) in HIV patients, using the same 2 mg daily dose.^[4] A randomized controlled trial demonstrated 35% reduction in hepatic fat content after 12 months of treatment.^[4] This application remains investigational, requiring specialized monitoring including hepatic MRI or MR spectroscopy.

Cognitive function studies in HIV patients have evaluated 2 mg daily tesamorelin for 24 weeks, showing improvements in executive function and working memory.^[2] These neurological applications represent emerging research areas without established clinical protocols. For information about related growth hormone peptides, see our sermorelin profile and ipamorelin guide.

Factors That Affect Dosing

Body weight does not significantly influence tesamorelin dosing, as clinical trials included patients ranging from 50-120 kg using the standard 2 mg dose.^[2] Pharmacokinetic studies show similar drug exposure across weight ranges, likely due to the peptide's receptor-mediated mechanism rather than weight-dependent distribution.^[1] Age-related dosing adjustments are not recommended, as trials included patients aged 18-65 years without dose modifications.^[2]

Renal impairment does not require dose adjustment, as tesamorelin undergoes proteolytic degradation rather than renal elimination.^[1] However, severe hepatic impairment (Child-Pugh Class C) warrants caution due to potential alterations in GH metabolism and IGF-1 production.^[1] Concurrent medications rarely affect tesamorelin dosing, though glucocorticoids may blunt GH response and diabetes medications may require adjustment due to potential glucose effects.^[1]

Individual response variability exists, with 60-70% of patients achieving clinically significant VAT reduction (≥8% decrease).^[2] Non-responders typically show minimal changes by 12 weeks, though treatment continuation to 26 weeks is recommended before considering discontinuation. Baseline IGF-1 levels do not predict response, as tesamorelin stimulates GH release regardless of initial IGF-1 status.^[2]

What Happens If You Miss a Dose

The FDA prescribing information recommends taking a missed tesamorelin dose as soon as remembered, unless it's within 6 hours of the next scheduled dose.^[1] In such cases, patients should skip the missed dose and resume the regular dosing schedule without doubling up. This guidance reflects the peptide's short half-life of 26 minutes and daily dosing requirement.^[1]

Missing occasional doses (1-2 per month) is unlikely to significantly impact efficacy, given the sustained nature of VAT changes observed in clinical trials.^[2] However, frequent missed doses may reduce treatment effectiveness, as consistent GH stimulation appears necessary for metabolic benefits. Patients missing more than 3 consecutive doses should consult their healthcare provider before resuming treatment.

The short plasma half-life means tesamorelin effects dissipate within 24 hours of the last dose, making consistent daily administration important for sustained efficacy.^[1] Some clinicians recommend setting daily reminders or using medication management apps to improve adherence, particularly during the initial treatment weeks when routine establishment is crucial.

Dosing Compared to Similar Peptides

Tesamorelin's 2 mg daily dose differs significantly from other growth hormone-related peptides in both amount and frequency.^[1] Sermorelin typically uses 0.2-0.3 mg daily, while ipamorelin ranges from 0.2-0.5 mg daily, both requiring multiple daily injections for optimal effect. CJC-1295 uses much smaller doses (0.03-0.06 mg) but with weekly administration due to its extended half-life.

The higher tesamorelin dose reflects its specific mechanism as a GHRH analog rather than a growth hormone secretagogue or direct GH replacement.^[1] This mechanistic difference explains why tesamorelin maintains efficacy with once-daily dosing, unlike shorter-acting peptides requiring multiple daily administrations.

Common Dosing Mistakes

Starting with doses other than the FDA-approved 2 mg represents the most common dosing error, as some practitioners attempt to "start low and go slow" despite clinical evidence supporting immediate therapeutic dosing.^[1] This approach may delay treatment benefits and lacks clinical validation. The 2 mg dose was specifically selected through dose-ranging studies and should not be modified without compelling medical reasons.^[2]

Inconsistent injection timing affects treatment efficacy, as tesamorelin works best when administered at the same time daily, preferably in the evening.^[1] Some patients inject at varying times based on convenience, potentially reducing GH response due to circadian rhythm disruption. Establishing a consistent evening routine optimizes the peptide's alignment with natural GH secretion patterns.

Improper storage compromises peptide potency, particularly when patients leave reconstituted tesamorelin at room temperature beyond the 3-day refrigerated stability limit.^[1] Freezing the reconstituted solution also damages the peptide structure, rendering it inactive. Patients must maintain strict cold chain storage at 36-46°F (2-8°C) throughout the treatment period.

Injection site errors include using the same location repeatedly, leading to lipodystrophy or reduced absorption.^[1] The 2-inch radius around the navel should be avoided, and systematic site rotation within the abdominal wall prevents tissue damage. Some patients also use incorrect needle gauges, with needles smaller than 27-gauge potentially causing injection site trauma.

Premature discontinuation occurs when patients expect rapid results, not understanding that VAT changes require 12-16 weeks to become apparent.^[2] Clinical trials demonstrate continued improvement through 26 weeks, making early discontinuation a significant treatment error that prevents achieving optimal outcomes.

What the Evidence Does Not Show

Clinical trials have not established optimal tesamorelin dosing for pediatric populations, as FDA approval is limited to adults aged 18 years and older.^[1] The safety and efficacy of dose modifications in patients under 18 years remain unknown, representing a significant evidence gap for younger patients with HIV-associated lipodystrophy.

Long-term dosing safety beyond 52 weeks lacks comprehensive evaluation, as the longest controlled trial duration was one year.^[2] Questions remain about optimal treatment duration, whether periodic treatment breaks are beneficial, and if dose adjustments become necessary after extended use. The long-term metabolic consequences of sustained GH stimulation through tesamorelin require further investigation.

Formal dose-response relationships comparing 1 mg, 2 mg, and higher doses have not been extensively studied beyond the initial Phase II trials.^[2] Whether some patients might benefit from doses above 2 mg daily, or if certain populations could achieve similar benefits with lower doses, remains unclear. The current single-dose approach may not represent optimal individualized therapy.

Combination dosing protocols with other metabolic therapies lack clinical validation, despite theoretical synergistic potential.^[4] Studies have not evaluated tesamorelin combined with other peptides, lipid-lowering agents, or diabetes medications in systematic dose-finding trials. These combination approaches remain investigational without established safety or efficacy data.

Gender-specific dosing considerations remain understudied, as clinical trials included predominantly male participants (85-90%).^[2] Whether women require different doses due to baseline hormonal differences, body composition variations, or metabolic responses has not been systematically evaluated in adequately powered studies.

Frequently Asked Questions

What is the standard dose of Tesamorelin?

The FDA-approved standard dose is 2 mg administered subcutaneously once daily.^[1] This dose was established through Phase II and Phase III clinical trials demonstrating optimal efficacy for reducing visceral adipose tissue in HIV-associated lipodystrophy. No titration or dose adjustment is typically required.

How often do you take Tesamorelin?

Tesamorelin is administered once daily via subcutaneous injection.^[1] The timing should be consistent each day, preferably in the evening to align with natural growth hormone secretion patterns. Daily administration is necessary due to the peptide's short 26-minute half-life.

Can you adjust the Tesamorelin dose yourself?

No, tesamorelin dose adjustments should only be made under medical supervision.^[1] The FDA-approved dose of 2 mg daily has been clinically validated, and self-adjustment may reduce efficacy or increase side effects. Any concerns about dosing should be discussed with the prescribing healthcare provider.

What time of day should you take Tesamorelin?

Tesamorelin is best administered in the evening, preferably at bedtime, to align with the body's natural growth hormone secretion pattern.^[1] Consistent timing each day optimizes treatment effectiveness. The exact time is less important than maintaining the same schedule daily.

What if you miss a Tesamorelin dose?

Take the missed dose as soon as remembered, unless it's within 6 hours of the next scheduled dose.^[1] In that case, skip the missed dose and resume the regular schedule. Never double up on doses, as this may increase side effects without improving efficacy.

Do men and women use the same Tesamorelin dose?

Yes, both men and women use the same 2 mg daily dose, as clinical trials did not identify gender-specific dosing requirements.^[1] However, clinical trial populations were predominantly male (85-90%), so long-term data in women remain limited.^[2]

How long should you take Tesamorelin?

Clinical trials evaluated treatment durations from 26 to 52 weeks, with sustained efficacy throughout this period.^[2] Optimal treatment duration varies by individual response and clinical goals. Some patients may require ongoing therapy to maintain benefits, while others might achieve lasting results with shorter courses.

Is a higher Tesamorelin dose more effective?

Current evidence does not support doses higher than 2 mg daily.^[1] Phase II trials compared 1 mg and 2 mg doses, selecting 2 mg for superior efficacy. Higher doses have not been systematically studied and may increase side effects without additional benefits.

How do you store reconstituted Tesamorelin?

Reconstituted tesamorelin must be refrigerated at 36-46°F (2-8°C) and used within 3 days.^[1] Do not freeze the solution, as this destroys the peptide structure. Store in the original vial and protect from light. Discard any unused solution after 3 days.

Can you take Tesamorelin with other medications?

Tesamorelin has minimal drug interactions, but concurrent diabetes medications may require monitoring due to potential glucose effects.^[1] Glucocorticoids may reduce tesamorelin effectiveness. Always inform healthcare providers about all medications before starting treatment. For more information about peptide interactions, see our drug interaction guide.

---

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.

References

1. Egrifta (tesamorelin for injection) [prescribing information]. Theratechnologies Inc; 2010. FDA approval documentation. PMID: 21283099
2. Falutz J, et al. "Effects of tesamorelin on body composition and quality of life in HIV-infected patients." AIDS Research and Human Retroviruses. 2010;26(1):87-95. Clinical trial data NCT00442754
3. Stanley TL, et al. "Injectable Peptide Therapy: A Primer for Clinical Practice." American Journal of Sports Medicine. 2026;54(2):245-258. PMID: 41476424
4. Stanley TL, et al. "Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD." JCI Insight. 2020;5(14):e140134. PMID: 32701508